Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19005284 | DRUG POWDERIZATION WITHIN VIALS | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18977541 | COMPOSITIONS AND COMPOUNDS CONTAINNG BETA-HYDROXYBUTYRATE AND ONE OR MORE AMINO ACIDS | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18744999 | Roflumilast Formulations with an Improved Pharmacokinetic Profile | June 2024 | November 2024 | Allow | 5 | 1 | 0 | No | No |
| 18670960 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | May 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 18665222 | SELENIUM DISULFIDE COMPOSITIONS FOR USE IN TREATING MEIBOMIAN GLAND DYSFUNCTION | May 2024 | June 2025 | Allow | 14 | 3 | 0 | Yes | No |
| 18662430 | METHOD OF IMPROVING FLAVOR OF A COMPOSITION OF (D)-BETA-HYDROXYBUTYRIC ACID AND (D)-1,3 BUTANEDIOL AND USE AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENT | May 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 18652380 | METAL OXIDE ENCAPSULATED DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAME | May 2024 | June 2025 | Allow | 14 | 1 | 0 | No | No |
| 18631405 | TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVE | April 2024 | March 2025 | Allow | 11 | 2 | 0 | No | No |
| 18606903 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18606925 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18606946 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18598377 | ACID/ANIONIC ANTIMICROBIAL AND VIRUCIDAL COMPOSITIONS AND USES THEREOF | March 2024 | April 2025 | Allow | 13 | 2 | 0 | No | No |
| 18597574 | Roflumilast Formulations with an Improved Pharmacokinetic Profile | March 2024 | May 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18595985 | 3, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE | March 2024 | January 2025 | Allow | 11 | 1 | 0 | No | No |
| 18591994 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS | February 2024 | July 2024 | Allow | 5 | 1 | 0 | No | No |
| 18425676 | PHARMACEUTICAL AEROSOL PRODUCT FOR ADMINISTRATION BY ORAL OR NASAL INHALATION | January 2024 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18418799 | PDE5 INHIBITOR POWDER FORMULATIONS AND METHODS RELATING THERETO | January 2024 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18541675 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER | December 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18535124 | BODY FLUID RESISTANT TISSUE ADHESIVES | December 2023 | January 2025 | Allow | 14 | 0 | 0 | No | No |
| 18535764 | METHODS OF REDUCING MAMMOGRAPHIC BREAST DENSITY AND/OR BREAST CANCER RISK | December 2023 | April 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18531229 | METHODS OF ADMINISTERING ANTI-EPILEPSY AGENTS AND TRANSPORT INHIBITORS TO A SUBJECT | December 2023 | January 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18503967 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | November 2023 | April 2025 | Allow | 17 | 1 | 0 | No | No |
| 18371071 | METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN | September 2023 | September 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18367405 | METHOD OF TREATING CARDIOVASCULAR EVENTS USING COLCHICINE CONCURRENTLY WITH AN ANTIPLATELET AGENT AND STATIN | September 2023 | October 2024 | Allow | 13 | 1 | 0 | No | No |
| 18367412 | TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVE | September 2023 | October 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18240406 | NALOXONE FORMULATIONS FOR SUBLINGUAL AND/OR BUCCAL ADMINISTRATION | August 2023 | January 2025 | Allow | 17 | 1 | 0 | No | No |
| 18365406 | METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS | August 2023 | April 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18353870 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | July 2023 | March 2024 | Allow | 8 | 1 | 0 | No | No |
| 18219556 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS | July 2023 | December 2024 | Allow | 17 | 0 | 0 | Yes | No |
| 18219090 | ANTIMICROBIAL AND ANTI-INFLAMMATORY COMPOSITIONS | July 2023 | January 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18219526 | COVID-19 BINDING AEROSOLS | July 2023 | January 2024 | Allow | 6 | 2 | 0 | No | No |
| 18219009 | COVID-19 BINDING AEROSOLS | July 2023 | September 2023 | Allow | 2 | 0 | 0 | No | No |
| 18214019 | Method of Treating or Preventing Alzheimers Disease | June 2023 | October 2023 | Allow | 4 | 1 | 0 | No | No |
| 18207931 | BEADED TOBACCO MATERIAL AND RELATED METHOD OF MANUFACTURE | June 2023 | September 2024 | Allow | 15 | 1 | 0 | No | No |
| 18331875 | METHOD OF ADMINISTRATION AND TREATMENT | June 2023 | January 2025 | Allow | 20 | 2 | 0 | No | No |
| 18319355 | Biomarkers For Neurodegenerative Disease | May 2023 | September 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18144470 | TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVE | May 2023 | November 2023 | Allow | 7 | 1 | 0 | No | No |
| 18144528 | TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVE | May 2023 | December 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18132480 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | April 2023 | August 2024 | Allow | 16 | 1 | 0 | No | No |
| 18130141 | DRUG POWDERIZATION WITHIN VIALS | April 2023 | October 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18122812 | SOFT GEL CAPSULE PREPARATIONS | March 2023 | August 2023 | Allow | 5 | 0 | 1 | Yes | No |
| 18184562 | EXPLOITING OXYGEN INHIBITED PHOTOPOLYMERIZATION WITHIN EMULSION DROPLETS FOR THE FABRICATION OF MICROPARTICLES WITH CUSTOMIZABLE SIZE, SHAPE AND INTERFACIAL AND MECHANICAL PROPERTIES | March 2023 | September 2024 | Allow | 18 | 1 | 0 | No | No |
| 18121162 | MOIST ORAL COMPOSITIONS | March 2023 | April 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18120305 | COVID-19 BINDING AEROSOLS | March 2023 | September 2023 | Allow | 6 | 1 | 1 | No | No |
| 18104530 | MULTIDRUG PAIN MANAGEMENT PACKAGE | February 2023 | October 2024 | Allow | 21 | 1 | 0 | No | No |
| 18157302 | METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDE | January 2023 | October 2024 | Allow | 21 | 1 | 0 | No | No |
| 18152240 | METHODS OF TREATING CHRONIC WOUNDS USING ELECTROSPUN FIBERS | January 2023 | September 2024 | Allow | 20 | 1 | 0 | No | No |
| 18149916 | HAIR GROWTH COMPOSITION AND METHOD FOR MAKING AND USING THE SAME | January 2023 | May 2025 | Allow | 28 | 0 | 0 | No | No |
| 18065368 | STABILIZED FORMULATIONS OF LIPID NANOPARTICLES | December 2022 | July 2024 | Allow | 19 | 1 | 0 | No | No |
| 18064396 | RUBBER-BASED SOFT GEL SKIN ADHESIVES | December 2022 | July 2024 | Allow | 19 | 1 | 0 | No | No |
| 17987095 | TREATMENT OF DIABETES MELLITUS | November 2022 | July 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17980827 | AMORPHOUS FORM OF TETRACYCLIC COMPOUND | November 2022 | October 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17973691 | COMPOSITIONS AND METHODS FOR LONG LASTING DISINFECTION | October 2022 | October 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17921141 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF IN TREATING PARKINSON'S DISEASE | October 2022 | April 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 17965220 | DRUG-LOADED MESOPOROUS SILICA NANOPARTICLE FOR PREVENTION AND TREATMENT OF BRAIN CANCERS OR BRAIN METASTASES | October 2022 | December 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17959091 | AN INSTANT UNDERWATER BIO-ADHESIVE CONTAINING CATECHOL MOIETIES AND WATER-RESISTANT CHOLESTEROL | October 2022 | October 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17936385 | EXTRACELLULAR MATRIX-BASED BIOADHESIVE | September 2022 | April 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 17898632 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders | August 2022 | September 2024 | Allow | 24 | 1 | 0 | No | No |
| 17882391 | NEUTRAL PH COMPOSITIONS OF DOCETAXEL AND HUMAN SERUM ALBUMIN | August 2022 | June 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17873800 | NEUTRAL PH COMPOSITIONS OF DOCETAXEL AND HUMAN SERUM ALBUMIN | July 2022 | June 2024 | Allow | 23 | 1 | 0 | No | No |
| 17869145 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | July 2022 | August 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17813055 | METOLAZONE EMULSION FORMULATION | July 2022 | June 2024 | Allow | 23 | 1 | 1 | No | No |
| 17867495 | NEUTRAL PH COMPOSITIONS OF DOCETAXEL AND HUMAN SERUM ALBUMIN | July 2022 | June 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17838534 | DELIVERY OF LIQUID COMPOSITION AND OXYGEN | June 2022 | April 2024 | Abandon | 22 | 2 | 0 | No | No |
| 17836854 | MOIST ORAL COMPOSITIONS | June 2022 | June 2025 | Allow | 36 | 1 | 0 | No | No |
| 17836836 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | June 2022 | May 2024 | Allow | 23 | 1 | 0 | No | No |
| 17836692 | ORAL COMPOSITION WITH BEET MATERIAL | June 2022 | June 2025 | Allow | 36 | 1 | 0 | No | No |
| 17836790 | ORAL COMPOSITIONS WITH REDUCED WATER ACTIVITY | June 2022 | June 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17743654 | METHOD FOR PREPARING MODIFIED STARCH, LIPOSOME AND METHOD FOR PREPARING LIPOSOME | May 2022 | May 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17739401 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | May 2022 | November 2024 | Abandon | 30 | 2 | 0 | Yes | No |
| 17738636 | Highly Elastic Medical Sealants for Flexible Soft Tissue | May 2022 | August 2024 | Allow | 27 | 2 | 1 | No | Yes |
| 17738801 | Nutraceutical Composition Comprising a Water-Soluble Fullerene and a Ketone | May 2022 | August 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17737725 | Methods Of Treating Dyskinesia And Related Disorders | May 2022 | March 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17774099 | USE OF IODIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY-ASSOCIATED CACHEXIA AND CARDIOTOXICITY | May 2022 | June 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17734796 | DELIVERY SYSTEMS BASED ON HYDROGEL COMPOSITIONS AND METHODS THEREOF | May 2022 | November 2023 | Allow | 18 | 0 | 0 | No | No |
| 17712601 | Nanofiber Structures and Methods of Use Thereof | April 2022 | February 2024 | Allow | 22 | 1 | 1 | No | No |
| 17712302 | SOFT GEL COMPOSITIONS AND CAPSULES MADE FROM THE SAME | April 2022 | March 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17765953 | HYDROPHOBICALLY-MODIFIED BIOPOLYMER MATERIALS | April 2022 | September 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17703238 | THERMOSENSITIVE BIO-ADHESIVE HYDROGEL FOR REMOVAL OF URETERAL AND RENAL STONES | March 2022 | October 2022 | Allow | 7 | 1 | 0 | No | No |
| 17761455 | COSMETIC | March 2022 | January 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17695687 | Metal Oxide Encapsulated Drug Compositions and Methods of Preparing the Same | March 2022 | February 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17642129 | ADDITIVE COMPOSITION FOR PREVENTING VITAMIN C PRECIPITATION | March 2022 | June 2025 | Allow | 39 | 2 | 0 | No | No |
| 17689666 | Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy | March 2022 | February 2024 | Allow | 23 | 1 | 0 | No | No |
| 17639454 | METHODS OF TRAPPING CRUSTACEANS | March 2022 | January 2025 | Allow | 35 | 1 | 0 | No | No |
| 17679682 | Highly Soluble Rebaudioside D | February 2022 | December 2023 | Allow | 22 | 1 | 0 | No | No |
| 17678672 | NUTRITIONAL COMPOSITION AND INFANT FORMULA FOR PROMOTING DE NOVO MYELINATION | February 2022 | January 2024 | Allow | 23 | 1 | 0 | No | No |
| 17591306 | 3, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE | February 2022 | December 2023 | Allow | 22 | 1 | 0 | No | No |
| 17631980 | BIOCIDAL DISPERSIONS FOR COATING COMPOSITIONS | February 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17631659 | Feed Stuff for Beneficial Organisms that can be used in Integrated Pest Management | January 2022 | March 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17583870 | BIOLOGICAL TRANSPLANTATION MATERIAL | January 2022 | April 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17579981 | PDE5 INHIBITOR POWDER FORMULATIONS AND METHODS RELATING THERETO | January 2022 | June 2023 | Allow | 17 | 2 | 0 | Yes | Yes |
| 17628400 | COSMETIC COMPOSITION COMPRISING AN ORAL CAPSULE CONTAINING HYALURONIC ACID AND WHEAT GRAIN OIL WITH PHYTOCERAMIDES | January 2022 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17577882 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER | January 2022 | October 2023 | Allow | 21 | 1 | 0 | No | No |
| 17440061 | METHOD FOR COATING INSOLUBLE SOLIDS | January 2022 | January 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17625964 | POLYURETHANE GELS | January 2022 | June 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17625474 | HAIR COSMETIC | January 2022 | March 2025 | Allow | 38 | 1 | 0 | No | No |
| 17570683 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | January 2022 | June 2022 | Allow | 5 | 1 | 0 | No | No |
| 17562787 | METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS | December 2021 | January 2024 | Allow | 25 | 1 | 0 | No | No |
| 17559074 | FATTY ACID AMIDES AND USES THEREOF IN THE TREATMENT OF NAUSEA | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17558195 | USE OF GABOXADOL, GANAXOLONE AND ALLOPREGNANOLONE TO TREAT MOVEMENT DISORDERS | December 2021 | September 2024 | Abandon | 32 | 2 | 0 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GEMBEH, SHIRLEY V.
With a 31.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GEMBEH, SHIRLEY V works in Art Unit 1615 and has examined 703 patent applications in our dataset. With an allowance rate of 76.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 23 months.
Examiner GEMBEH, SHIRLEY V's allowance rate of 76.8% places them in the 35% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by GEMBEH, SHIRLEY V receive 1.66 office actions before reaching final disposition. This places the examiner in the 46% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by GEMBEH, SHIRLEY V is 23 months. This places the examiner in the 74% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +26.4% benefit to allowance rate for applications examined by GEMBEH, SHIRLEY V. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 31.2% of applications are subsequently allowed. This success rate is in the 55% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 43.9% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 73.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 58% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 63.5% of appeals filed. This is in the 37% percentile among all examiners. Of these withdrawals, 42.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 44.8% are granted (fully or in part). This grant rate is in the 49% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 47% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.